Jiangsu Huitong Pharmaceutical

Jiangsu Huitong Pharmaceutical Technology is a Chinese biotechnology company specializing in the research, development, and large-scale manufacturing of therapeutic monoclonal antibodies and biosimilars. Founded in 2011 and based in the China Medical City of Taizhou, the company focuses on high-expression cell line construction and advanced protein purification technologies. In 2017, it was integrated into Mabwell (Shanghai) Bioscience as a core subsidiary, serving as a primary R&D and industrialization base for the group's biologics portfolio. The company has successfully commercialized several biosimilars in China, including treatments for osteoporosis and rheumatoid arthritis, while maintaining a robust pipeline in oncology and bone metabolism. Its facilities are equipped with significant GMP-compliant production capacity to support both domestic and international commercialization efforts.